Summarized by Masters of Longevity from Fight Aging!.
Assessment of evidence and debate over whether GLP-1 receptor agonists should be classified as geroprotective therapies rather than primarily weight-loss drugs, reviewing clinical trials, epigenetic clock data, and proposed mechanisms.
Key Takeaways
- The SELECT trial reported a 19% reduction in all-cause mortality with GLP-1 RA treatment in people with obesity without diabetes.
- The FLOW trial found a 24% reduction in a primary kidney composite endpoint associated with GLP-1 RA therapy.
- A 2025 randomized study reported significant deceleration of DunedinPACE, PCGrimAge, and PhenoAge after 32 weeks of semaglutide therapy.
